In particular, tumor-infiltrating lymphocyte (TIL) markers, such as CD4, CD8, CD45RO, and FOXP3, and intratumor budding (ITB) have been identified as markers predicting the pathological response to nCRT in rectal cancer [6–11]. Here, CD8A is linked to neoplasm.